MedTrace Logo

Sustained Mood Improvement With Laughing Gas Exposure

NCT07262008 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2025-12-10

No results posted yet for this study

Summary

Multi-centre, parallel group, blinded, 1:1 randomized controlled trial to determine the effect of nitrous oxide on reducing symptoms of depression in patients with treatment resistant depression.

Conditions

Interventions

DRUG

Inhalation of Nitrous oxide (Laughing gas) + intravenous saline

Nitrous oxide at an inspiratory concentration of 50% with concurrent intravenous saline (20ml) for one hour.

DRUG

inhalation of %100 oxygen + intravenous midazolam

Inspiration of 100% oxygen with concurrent intravenous midazolam (0.02mg/kg, up to 2 mg) for one hour.

Sponsors & Collaborators

  • Anesthesia Clinical Trials Unit (Department of Anesthesia and Pain Management)

    collaborator UNKNOWN

  • University Health Network, Toronto

    collaborator OTHER

  • Sunnybrook Health Sciences Centre

    collaborator OTHER

  • Unity Health Toronto

    collaborator OTHER

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • Women's College Hospital

    lead OTHER

Principal Investigators

  • Karim Ladha, MD · Women's College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-01
Primary Completion
2027-02-01
Completion
2028-09-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07262008 on ClinicalTrials.gov